Axsome Therapeutics, Inc. (AXSM) Balance Sheet

Asset growth has been funded largely by liabilities rather than retained value creation, since retained earnings remain near -$1.4B and have barely improved. The balance sheet is expanding in scale but not in net worth, which suggests the company's commercial build is being financed through obligations whose durability should be monitored. Investors should watch whether equity stabilizes as operating losses narrow.

Total debt has been broadly flat near $190M to $220M across the period, meaning the rise in liabilities has come mostly from operating obligations rather than new borrowing. The leverage ratio is high for a company without consistent profitability, which suggests cash flow durability is the key variable for servicing these obligations. Refinancing terms and maturity profile warrant further investigation.

Cash has remained in a $300M to $327M band for ten quarters, implying that reserves are being consumed by operations at roughly the rate they are replenished. The falling current ratio signals that short-term obligations have grown more quickly than current assets, which may compress flexibility if prescription growth slows. The liquidity buffer appears adequate today but is not expanding.

The deficit has grown steadily from roughly -$983M in Q2 2024, reflecting cumulative losses that stock-based compensation has likely contributed to alongside operating expenses. Equity quality is therefore weak on a historical basis, and dilution risk remains a relevant consideration for holders. Narrowing quarterly losses are a positive development but do not yet reverse the cumulative erosion.